Stocks In Focus For Tuesday 07/14/15 – AVXL MHCC TAUG

Sign Up For Our FREE E-mail Newsletter-> HERE <-To Receive Our Penny Stock Expert Picks Now!

Remember to visit our Twitter page for real-time updates, click here: Penny Stock Experts

Hi Everyone & Welcome New Subscribers,

AVXL (Anavex Life Sciences Corp.) started the week off strong, leading U.S. listed OTC stocks below $1.00 in overall dollar volume, and closed up a modest 2.21%. As we’ve mentioned before, the Company plans to announce Phase 2a clinic trial results next Wednesday, July 22nd, at the Alzheimer’s Association International Conference; read more, HERE.

MHCC (Millennium Healthcare, Inc.) – Potential Bottom – shares closed up a sweet 27.78% on the day, as bulls and bears continue to fight at support levels near the psychological .01 area, holding that level as a low today and ending up at .012. If the stock can trade 10 million shares to the positive side again tomorrow, the seller might back off and let the stock run back up some. Keep it on your watch list.

TAUG (Tauriga Sciences, Inc.) – Volume/Potential Continued Breakout – had a very strong start to the week, following an update from the company this morning, and closed up over 30% on the day with it’s highest volume traded in a year. Watch for a break past today’s high of .0049, and the .005 level, to spur a potentially trend reversal play.

Daily e-mail alerts will be soon forthcoming, so make sure you sign up now to join our winning trading team!

Sign up-> NOW <-To Join Our E-mail List!

Happy Trading!


The Penny Stock Experts Team At 

Please read our legal Disclaimer below:

This disclaimer is to be read in its entirety, and fully understood before using or joining the email list. reserves the right to revise, amend, or modify our Privacy Policy, our Disclaimer, and our other policies and agreements at any time and in any manner by updating their postings. You are responsible for regularly reviewing these terms, conditions, and notices, and any additional terms posted on Your continued use of the website and/or email newsletter after the effective date of such changes constitutes your acceptance of and agreement to such changes. If we should update this disclaimer, we will post the updates to this page on DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. 

Neither nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered st ock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.

We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website.

Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that and it’s affiliates can buy or sell more shares at any time. We can add or decrease this position at anytime following this e-mail or post. and/or it’s affiliates may receive compensation for e-mail alerts.

To view our full compensation disclosure please visit does not accept free-trading shares as a form of payment.

We hold up to 20,000 shares of AVXL (Anavex Life Sciences, Inc.) which we have purchased on the open market and can sell at any time following this post.